We are focused on creating genuinely innovative medicines and improving access to them. In this way, we deliver the greatest benefit to patients, healthcare systems and societies globally.
We have three priorities designed to deliver our growth through innovation strategy.

Accelerating the next wave of new molecular entities, building our capabilities in immunology and rare diseases, pursuing new scientific modalities and driving R&D productivity

Meeting our growth and profitability goals through successful innovation and commercial excellence, as well as completing the Alexion acquisition

Contributing to the enterprise and to society, with a focus on inclusion and diversity, lifelong learning, improving access to healthcare, environmental protection, and ethics and transparency, as well as delivering our Ambition Zero Carbon programme
Our business is organised to deliver our growth through innovation strategy and our three strategic priorities.
Our R&D and Commercial functions have been organised to accelerate decision making and the launches of new medicines across our main disease areas where we believe we can make the most meaningful difference to patients.

Inspired by our Values and what science can do, we are focused on accelerating the delivery of life-changing medicines that create enduring value for patients and society.
We are committed to operating in a way that recognises the interconnection between business growth, the needs of society and the limitations of our planet.